Testing Safety and Feasibility of Inhaled Hydrogen Gas During Extracorporeal Cardiopulmonary Resuscitation in Children and Young Adults with Cardiac Arrest
Led by Boston Children's Hospital · Updated on 2025-07-03
53
Participants Needed
4
Research Sites
21 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to test the feasibility and safety of inhaled hydrogen gas H2 as a rescue therapy during cardiac arrest requiring extracorporeal cardiopulmonary resuscitation ECPR in patients with cardiac conditions like congenital heart disease. The trial addresses the challenge of neurologic and kidney injuries caused by ischemia and reperfusion during ECPR. Preclinical studies showed that hydrogen inhalation may reduce damage after ischemic events, and early human safety studies found no significant adverse effects from inhaling 2.4% hydrogen gas.
Participants are randomly assigned to one of two groups usual care alone or usual care plus inhaled 2% hydrogen gas administered via mechanical ventilator and ECMO membrane for 72 hours. This early-phase, single-blind randomized trial includes a small initial phase and will enroll patients undergoing ECPR for refractory cardiac arrest. The hydrogen gas dosing is continuous during the first 72 hours after resuscitation, with oxygen levels adjusted by the clinical team.
During the study, researchers will monitor how well the hydrogen gas can be delivered, safety over 30 days, and secondary measures such as survival to hospital discharge, duration of ICU and hospital stays, and functional status up to 12 months. Participants are closely observed in cardiac intensive care, with assessments including safety events and feasibility of treatment administration. The total participation duration includes 30 days for safety monitoring and up to 12 months for longer-term outcomes.
CONDITIONS
Brief Title
Hydrogen's Feasibility and Safety as a Therapy in ECPR
Research Team
J
John N Kheir, MD
V
Victoria Habet, DO
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Hydrogen Gas (2%) with Usual Care
Usual Care Alone
What it is
Hydrogen gas (2%) delivered via the ventilator and ECMO membrane for 72 hours, given as an adjunct to usual post-ECPR care.
Usual post-ECPR care, including targeted temperature management, without adjunct hydrogen gas therapy.
Role in trial
Investigational therapy tested for feasibility and safety as an adjunct in post-ECPR care for refractory cardiac arrest in children and young adults.
Control condition representing current standard management after ECPR in the study population.
Primary use or purpose
Being studied for the feasibility and safety of hydrogen gas administration during early post-ECPR period in pediatric refractory cardiac arrest with cardiac comorbidity.
Represents post-ECPR standard management for refractory cardiac arrest, used as the control in the trial.
How it is given or performed
Hydrogen gas (2%) is given via the ventilator and ECMO membrane continuously for 72 hours. Oxygen concentration is adjusted per clinical team discretion.
Participants receive usual post-ECPR intensive care, which may include targeted temperature management and other protocolized supportive measures, but no adjunct gas therapy is added.
Evidence status
Efficacy and safety are under prospective evaluation; no published outcome results are available yet. Evidence for hydrogen in this setting remains investigational.
Represents established supportive care for pediatric ECPR, reflecting current practice; outcomes for this group represent clinical routine but trial-specific results are not yet available.
Important limitations
Hydrogen therapy is experimental in this context, and potential benefits or risks are not yet established. The small pilot cohort and early feasibility focus limit broader conclusions until results are reported.
Outcomes in the control arm may be limited by the single-study setting and sample size. No published trial-specific outcome data are available yet; findings may not generalize beyond the study context.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
All Ages
All Genders
Eligibility Criteria
You may qualify if you...
Patients admitted to a cardiac intensive care unit with cardiac comorbidity such as congenital heart disease, myocarditis, arrhythmia, or heart transplant rejection
Patients anticipated to be between birth and 18 years old, with occasional enrollment of patients over 18
Patient experiencing refractory cardiac arrest lasting more than 5 minutes and receiving ongoing CPR in ICU, catheterization lab, or operating room
Clinical decision to use extracorporeal cardiopulmonary resuscitation (ECPR) due to lack of other options
You will not qualify if you...
Enrollment in the opt-out program
Known pregnancy
Patients who are prisoners
Prior ECPR episode during the current admission
Enrollment not occurring within 6 hours of decision to use ECPR
ECMO cannulation without preceding CPR (does not qualify as ECPR)
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - 72 hours
Participants receive hydrogen gas (2%) administered via mechanical ventilator and ECMO membrane for 72 hours as a rescue therapy during extracorporeal cardiopulmonary resuscitation (ECPR).
Continuous treatment during 72 hours
Follow-up
Duration - Up to 12 months
Participants are monitored for safety and outcomes including survival, ICU and hospital length of stay, and functional status for up to 12 months after treatment.
Periodic assessments during follow-up
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Evaluating Nebulized Amikacin Plus Standard Care
Versus Standard Care Alone for Gram-negative Pneumonia
in Patients Receiving Veno-arterial ECMO Support
Evaluating Accuracy of FloPatch FP120 Doppler Ultrasound Compared to Manual Pulse Checks in Cardiac Arrest Patients
Study of Willem17 AI Software for ECG Analysis in Patients With High-Risk Cardiac Conditions
Monitoring Brain Blood Flow and Cerebral Autoregulation in Critically Ill Children Using Transcranial Doppler A Prospective Observational Study
Brain and Heart Interactions in Comatose Patients After Cardiac Arrest
Ancillary Study of the HEAVENwARd Trial
Study of Butylphthalide to Improve Brain Function After Cardiac Arrest in Adults Aged 18 to 80
Randomized, Double-Blind, Placebo-Controlled Trial
Trial of a Combined Device Approach to Improve Survival After Out-of-Hospital Cardiac Arrest
China Registry Study on Extracorporeal Membrane Oxygenation ECMO Support for Heart and Lung Failure Patients
Using Advanced Brain MRI Scans to Predict Neurological Recovery in Coma Patients After Cardiac Arrest
Evaluation and Comparison of Early Brain Damage Scoring Systems at ICU Admission Following Cardiac Arrest
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Hydrogen's Feasibility and Safety as a Therapy in Extracorporeal Cardiopulmonary Resuscitation (Hydrogen-FAST): study protocol for a trial of inhaled hydrogen gas as an adjunctive therapy in refractory cardiac arrest.